tiprankstipranks
Trending News
More News >
Progyny (PGNY)
NASDAQ:PGNY
US Market
Advertisement

Progyny (PGNY) AI Stock Analysis

Compare
648 Followers

Top Page

PGNY

Progyny

(NASDAQ:PGNY)

Rating:74Outperform
Price Target:
$25.00
▲(10.86% Upside)
Progyny's strong financial performance and positive earnings call outlook are the most significant factors driving the score. Technical indicators suggest a neutral trend, while the high P/E ratio indicates a relatively expensive valuation. The company's strategic initiatives and increased guidance provide a positive outlook despite some challenges.
Positive Factors
Financial Performance
Results came in ahead of expectations and were accompanied by a guidance raise, with the company once again benefiting from favorable utilization.
Investor Confidence
Progyny is getting its mojo back as it tries to restore investor confidence after last year's utilization and consumption variability, and the loss of Amazon's large book-of-business.
Revenue Growth
PGNY increased 2025 revenue guidance, showing confidence in future growth despite macro uncertainties.
Negative Factors
Client Growth
The number of lives added this selling season is trailing last year's levels.
Client Wins
Commentary around lower average lives per client this selling season spurred some questions around new client wins.
Stock Volatility
The initial volatile stock reaction following the print, trading up in the after-market, then down as much as ~8%, illustrates some investor nervousness on the stock.

Progyny (PGNY) vs. SPDR S&P 500 ETF (SPY)

Progyny Business Overview & Revenue Model

Company DescriptionProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
How the Company Makes MoneyProgyny generates revenue primarily through its fertility benefits management services, which it provides to employers as part of their employee benefits packages. The company charges employers a fee based on the number of employees covered under its fertility benefit plans. Key revenue streams include fees for plan administration and management, as well as commissions from fertility clinics within its extensive network. Additionally, Progyny has established strategic partnerships with various employers and health insurance providers, which help to broaden its reach and enhance its service offerings, ultimately contributing to its earnings.

Progyny Key Performance Indicators (KPIs)

Any
Any
Fertility and Family Building Clients
Fertility and Family Building Clients
Chart InsightsProgyny's client base has shown robust growth, nearly doubling from 2023 to 2025. This expansion is supported by strategic acquisitions and partnerships, such as with OURA and Amazon, enhancing their service offerings. Despite the impact of a large client transition, the company maintains strong client retention and upselling, reflected in increased full-year revenue guidance. The record number of ART cycles and diversified market reach underscore Progyny's resilience and strategic focus on expanding client relationships and product portfolio.
Data provided by:Main Street Data

Progyny Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call indicates strong financial performance and growth, with record results and positive client expansion. While there are challenges such as the impact of a large client transition and slower initial pipeline build, the company's strategic initiatives and increased full-year guidance highlight a positive outlook.
Q2-2025 Updates
Positive Updates
Record Quarterly Results
The company reported record quarterly results with strong growth in both revenue and adjusted EBITDA, along with gross margin expansion and significant cash flow generation.
Revenue Growth
Second quarter revenue grew 9.5% over the prior year to $332.9 million, primarily due to an increase in the number of clients and covered lives.
Client and Covered Lives Expansion
Progyny had 542 clients with at least 1,000 lives, representing an average of 6.74 million covered lives in the quarter, compared to 463 clients and 6.41 million covered lives a year ago.
Positive Client Retention and Expansion
Early activity in renewals has been positive with clients not looking to reduce benefits and many expanding their offerings.
Strategic Acquisitions and Partnerships
The integration of BenefitBump is complete, and Progyny has formed a new partnership with OURA. The company was also chosen by Amazon for its Health Benefits Connector program.
Increased Full Year Guidance
Progyny raised its full year guidance, projecting revenue of between $1.235 billion to $1.270 billion, reflecting growth of between 5.8% and 8.8%.
Negative Updates
Impact of Large Client Transition
The second quarter included the final contribution from a large former client, impacting revenue by $17.2 million. Future quarters will not include this contribution.
Slower Initial Pipeline Build
The sales year began with a slower pacing in the build of Q1 pipeline due to macroeconomic uncertainties, though it has since picked up.
Lower Lives from Early Wins
Early commitments in the selling season have a lower number of lives compared to last year due to differences in the demographics of new clients.
Company Guidance
During the second quarter of 2025 earnings call, Progyny, Inc. provided updated guidance reflecting strong financial performance and increased expectations for the year. The company reported a 9.5% revenue growth to $332.9 million, with adjusted EBITDA increasing by 6% to $58 million. The company also raised its full-year revenue guidance to between $1.235 billion and $1.270 billion, reflecting growth of up to 8.8%. Progyny noted a record 17,000 ART cycles performed in the quarter, contributing to an 18% revenue increase in its core business, excluding a large former client. The company also highlighted its strategic initiatives, including expanding client relationships, product portfolio enhancements, and successful integration of recent acquisitions. Progyny's market reach continued to diversify, spanning various sectors, and it maintained a strong focus on client retention and upselling. Additionally, the company secured a revolving credit facility to enhance financial flexibility.

Progyny Financial Statement Overview

Summary
Progyny exhibits strong financial performance with significant revenue growth, robust profit margins, and effective cash management. The income statement shows a 54% revenue increase, while the balance sheet reflects low leverage and strong equity. Cash flow is strong, supporting growth initiatives.
Income Statement
92
Very Positive
Progyny demonstrates strong revenue growth with a significant increase in total revenue from $786.91M in 2022 to $1.21B in TTM (Trailing-Twelve-Months), marking a 54% growth rate over this period. The gross profit margin remains robust at approximately 22%, and the net profit margin is healthy at 4.33% for TTM. The EBIT and EBITDA margins are stable, reflecting operational efficiency. Overall, the company shows strong revenue growth and profitability.
Balance Sheet
85
Very Positive
Progyny maintains a solid financial position with a low debt-to-equity ratio of 0.06 in TTM, indicating low financial leverage. The return on equity (ROE) stands at 11.23%, showcasing effective use of shareholder funds. The equity ratio is strong at 64%, indicating a healthy balance between debt and equity financing. The company’s balance sheet reflects stability and financial health with manageable liabilities.
Cash Flow
90
Very Positive
Progyny demonstrates strong cash flow performance with a free cash flow growth rate of 12.73% from 2024 to TTM. The operating cash flow to net income ratio is high at 3.87, indicating excellent cash conversion efficiency. The free cash flow to net income ratio is also favorable at 3.73, highlighting robust cash generation relative to net income. Overall, the cash flow position is strong, supporting the company's growth initiatives.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.24B1.17B1.09B786.91M500.62M344.86M
Gross Profit277.44M253.36M238.80M167.32M112.14M70.06M
EBITDA82.67M67.45M64.47M24.94M33.64M10.25M
Net Income53.12M54.34M62.04M30.36M65.77M46.46M
Balance Sheet
Total Assets760.95M607.10M756.62M542.99M358.06M253.93M
Cash, Cash Equivalents and Short-Term Investments305.09M227.95M371.09M189.30M119.42M109.30M
Total Debt25.50M19.27M19.39M7.71M8.65M9.55M
Total Liabilities245.93M185.04M203.19M166.02M106.24M86.98M
Stockholders Equity515.02M422.06M553.43M376.97M251.82M166.95M
Cash Flow
Free Cash Flow190.20M173.70M185.17M77.15M23.91M35.17M
Operating Cash Flow202.00M179.10M188.81M80.39M26.04M36.20M
Investing Cash Flow-34.17M195.79M-200.53M-43.87M8.77M-40.03M
Financing Cash Flow-125.30M-309.88M-11.07M-7.86M-13.70M-6.25M

Progyny Technical Analysis

Technical Analysis Sentiment
Negative
Last Price22.55
Price Trends
50DMA
22.90
Negative
100DMA
22.38
Positive
200DMA
20.99
Positive
Market Momentum
MACD
0.11
Positive
RSI
45.73
Neutral
STOCH
59.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGNY, the sentiment is Negative. The current price of 22.55 is below the 20-day moving average (MA) of 23.00, below the 50-day MA of 22.90, and above the 200-day MA of 20.99, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 45.73 is Neutral, neither overbought nor oversold. The STOCH value of 59.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PGNY.

Progyny Risk Analysis

Progyny disclosed 57 risk factors in its most recent earnings report. Progyny reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Progyny Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$2.03B40.0010.94%9.62%-6.61%
66
Neutral
$1.49B43.105.27%3.20%
66
Neutral
$1.87B-8.76%15.31%77.02%
61
Neutral
$2.17B116.053.56%3.28%-24.79%-78.38%
55
Neutral
$1.35B-14.18%-2.57%79.86%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
50
Neutral
$1.40B-44.40%18.59%10.96%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PGNY
Progyny
22.55
-0.99
-4.21%
PINC
Premier
25.85
6.89
36.34%
TDOC
Teladoc
7.82
0.63
8.76%
PHR
Phreesia
28.13
4.22
17.65%
SDGR
Schrodinger
19.13
-0.95
-4.73%
GDRX
GoodRx Holdings
4.00
-3.82
-48.85%

Progyny Corporate Events

Private Placements and FinancingFinancial Disclosures
Progyny Secures $200M Credit Facility with JPMorgan
Positive
Jul 8, 2025

On July 1, 2025, Progyny, Inc. entered into a $200 million revolving credit facility with JPMorgan Chase Bank, enhancing its operational and financial flexibility. Despite no immediate plans to utilize the facility, the favorable market conditions made it an opportune time for the transaction. Progyny also announced that its second-quarter financial results for 2025 are expected to slightly exceed previous guidance, reflecting favorable member activity and continued strong performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025